Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults

Table 3 Result of base case analysis

Treatment order	2-year expected cost (USD)	Expected period of the PL ≥ 30 × 10⁹/L (years)*	Deaths^†	Manifesting AE^†,‡,§	Emergency treatment^†	Cost-effectiveness ratio^\|\|
Sequence 1	40,980	1.75	87.02	224.47	140.96	23,438
Sequence 2	39,822	1.79	85.44	114.78	110.66	22,280
Sequence 3	33,551	1.78	85.65	106	128.83	18,826

PL: platelet, AE: adverse event.
*The period was calculated as N_S · P/N_T, where N_S, P, and N_T denote the average number of people in the PL ≥ 30 × 10⁹/L states in the simulated population, the duration of simulation (2 years), and the total number of people simulated, respectively (10,000).
^†The number of patients among 10,000 people.
^‡Assuming sepsis would occur during the splenectomy and rituximab treatment period as well as after treatment. Pulmonary embolism was assumed to be the adverse event for romiplostim treatment.
§Using these AE incidence rates as the rates of transition among the states of the Markov model to a state of “treatment for AE,” we calculated the number of people who developed adverse events in 2 years in a 10,000-person population.
|| Two-year expected cost (USD)/period of PL ≥ 30 × 10⁹/L (years).

ISSN: 1472-6963